Akers Biosciences, Inc. Akers' Management System Certified to ISO 13485
February 09 2015 - 7:00AM
RNS Non-Regulatory
TIDMAKR
Akers Biosciences, Inc.
09 February 2015
9 February 2015
Akers' Management System Certified to ISO 13485 (2003)
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers" or
the "Company"), a medical device company focused on reducing the
cost of healthcare through faster, easier diagnosis, announces that
the Company's Management System has been certified by SAI Global, a
leading global management systems Certification Body, to ISO 13485
(the "Certification"). The Certification is a requirement in
certain countries to enable regulatory approval of medical
devices.
ISO 13485 is an International Organization for Standardization
(ISO) standard, published in 2003, that represents the requirements
for a comprehensive quality management system for the design and
manufacture of medical devices.
"Given the Company's strategy to expand sales internationally,
achieving this quality standard is a vital step towards our
expansion," said Executive Chairman, Raymond F. Akers Jr., Ph.D.
"As well as demonstrating to future potential partners and
distributors the Company's commitment to a quality management
system, it may also help accelerate the process of gaining
regulatory clearance for medical devices in certain countries,
allowing us to get products to market faster," continued Dr.
Akers.
ABOUT AKERS BIOSCIENCES, INC.
Akers Biosciences develops, manufactures, and supplies rapid
screening and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical products distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbiosciences.com. Follow us on Twitter
@AkersBio.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934, as amended. Such forward-looking statements reflect
the Company's expectations about its future operating results,
performance and opportunities that involve substantial risks and
uncertainties. These statements include but are not limited to
statements regarding the intended terms of the offering, closing of
the offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
For more information:
Akers Biosciences, Inc.
Raymond F. Akers, Jr. PhD
Executive Chairman of the Board
Tel. +1 856 848 8698
RedChip Companies, Inc. (US Investor Relations)
Jon Cunningham
Tel. +1 407 644 4256 x107
finnCap (UK Nominated Adviser and Broker)
Geoff Nash / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel: +44 (0)20 7220 0500
Vigo Communications (UK Investor Relations)
Ben Simons / Alexandra Roper
Tel. +44 (0)20 7016 9570
Email. akers@vigocomms.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALLFFLFLIAIIE
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Apr 2023 to Apr 2024